Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
PCYC's Cash to Debt is ranked higher than
78% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. PCYC: No Debt )
PCYC' s 10-Year Cash to Debt Range
Min: 0.1   Max: 26993.8
Current: No Debt

0.1
26993.8
Equity to Asset 0.80
PCYC's Equity to Asset is ranked higher than
83% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. PCYC: 0.80 )
PCYC' s 10-Year Equity to Asset Range
Min: 0.6   Max: 0.98
Current: 0.8

0.6
0.98
Interest Coverage No Debt
PCYC's Interest Coverage is ranked higher than
89% of the 577 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PCYC: No Debt )
PCYC' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 5
Z-Score: 33.73
M-Score: -0.92
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) 20.39
PCYC's Operating margin (%) is ranked higher than
92% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.88 vs. PCYC: 20.39 )
PCYC' s 10-Year Operating margin (%) Range
Min: -24376.8   Max: 37.64
Current: 20.39

-24376.8
37.64
Net-margin (%) 15.43
PCYC's Net-margin (%) is ranked higher than
91% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.05 vs. PCYC: 15.43 )
PCYC' s 10-Year Net-margin (%) Range
Min: -23291.71   Max: 25.76
Current: 15.43

-23291.71
25.76
ROE (%) 13.60
PCYC's ROE (%) is ranked higher than
93% of the 1143 Companies
in the Global Biotechnology industry.

( Industry Median: -35.75 vs. PCYC: 13.60 )
PCYC' s 10-Year ROE (%) Range
Min: -318.92   Max: 17.64
Current: 13.6

-318.92
17.64
ROA (%) 10.98
PCYC's ROA (%) is ranked higher than
94% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. PCYC: 10.98 )
PCYC' s 10-Year ROA (%) Range
Min: -127.89   Max: 13.57
Current: 10.98

-127.89
13.57
ROC (Joel Greenblatt) (%) 368.93
PCYC's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. PCYC: 368.93 )
PCYC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -5354.61   Max: 460.92
Current: 368.93

-5354.61
460.92
Revenue Growth (%) 161.00
PCYC's Revenue Growth (%) is ranked higher than
99% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. PCYC: 161.00 )
PCYC' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 166.8
Current: 161

0
166.8
» PCYC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

PCYC Guru Trades in Q4 2013

Steven Cohen 939,713 sh (+133.88%)
Mariko Gordon 4,376 sh (+130.07%)
Murray Stahl 5,075 sh (+81.19%)
Mariko Gordon 5,300 sh (unchged)
Jim Simons Sold Out
PRIMECAP Management 2,380,739 sh (-0.02%)
» More
Q1 2014

PCYC Guru Trades in Q1 2014

Joel Greenblatt 9,591 sh (New)
Jim Simons 47,700 sh (New)
Mariko Gordon 9,295 sh (+112.41%)
Murray Stahl 6,864 sh (+35.25%)
PRIMECAP Management 2,380,739 sh (unchged)
Steven Cohen 388,523 sh (-58.66%)
» More
Q2 2014

PCYC Guru Trades in Q2 2014

Ken Fisher 5,114 sh (New)
Joel Greenblatt 79,089 sh (+724.62%)
Murray Stahl 8,783 sh (+27.96%)
Jim Simons 60,400 sh (+26.62%)
Mariko Gordon 4,000 sh (unchged)
Steven Cohen 574,900 sh (unchged)
Mariko Gordon Sold Out
PRIMECAP Management 2,313,039 sh (-2.84%)
» More
Q3 2014

PCYC Guru Trades in Q3 2014

Steven Cohen Sold Out
Jim Simons Sold Out
Joel Greenblatt Sold Out
PRIMECAP Management 2,311,039 sh (-0.09%)
Murray Stahl 7,003 sh (-20.27%)
Ken Fisher 3,244 sh (-36.57%)
» More
» Details

Insider Trades

Latest Guru Trades with PCYC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-09-30 Sold Out 0.09%$91.5 - $127.81 $ 133.3416%0
Ken Fisher 2014-09-30 Reduce -36.57%$91.5 - $127.81 $ 133.3416%3244
Joel Greenblatt 2014-06-30 Add 724.62%0.08%$85.85 - $107.42 $ 133.3442%79089
Mariko Gordon 2014-06-30 Sold Out 0.04%$85.85 - $107.42 $ 133.3442%0
Ken Fisher 2014-06-30 New Buy$85.85 - $107.42 $ 133.3442%5114
Mariko Gordon 2014-03-31 Add 112.41%0.02%$100.49 - $151.61 $ 133.343%9295
Joel Greenblatt 2014-03-31 New Buy0.01%$100.49 - $151.61 $ 133.343%9591
Mariko Gordon 2013-12-31 Add 130.07%0.01%$99.28 - $139.59 $ 133.3410%4376
Mariko Gordon 2013-09-30 New Buy0.01%$84.5 - $132.49 $ 133.3420%1902
Joel Greenblatt 2013-03-31 Sold Out 0.14%$57.78 - $94.2 $ 133.3472%0
Joel Greenblatt 2012-12-31 New Buy0.14%$47.87 - $69.78 $ 133.34127%41832
George Soros 2012-06-30 Sold Out 0.04%$25.72 - $53.44 $ 133.34309%0
George Soros 2012-03-31 New Buy0.04%$14.99 - $28.68 $ 133.34538%100000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Pharmacyclics Inc

Weekly Insider Sells Highlight: BX, PCYC, MAS, ITMN
According to GuruFocus Insider Data, the largest insider sells during the past week were: Blackstone Group LP, Pharmacyclics Inc., Masco Corporation and InterMune Inc. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 120.10
PCYC's P/E(ttm) is ranked higher than
89% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PCYC: 120.10 )
PCYC' s 10-Year P/E(ttm) Range
Min: 35.9   Max: 496.74
Current: 120.1

35.9
496.74
P/B 13.68
PCYC's P/B is ranked higher than
62% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 6.13 vs. PCYC: 13.68 )
PCYC' s 10-Year P/B Range
Min: 0.24   Max: 35.11
Current: 13.68

0.24
35.11
P/S 18.16
PCYC's P/S is ranked higher than
76% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 28.86 vs. PCYC: 18.16 )
PCYC' s 10-Year P/S Range
Min: 10.87   Max: 617
Current: 18.16

10.87
617
PFCF 83.46
PCYC's PFCF is ranked higher than
92% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PCYC: 83.46 )
PCYC' s 10-Year PFCF Range
Min: 8.05   Max: 218.11
Current: 83.46

8.05
218.11
EV-to-EBIT 79.52
PCYC's EV-to-EBIT is ranked higher than
88% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PCYC: 79.52 )
PCYC' s 10-Year EV-to-EBIT Range
Min: -28.2   Max: 400.3
Current: 79.52

-28.2
400.3
Shiller P/E 636.51
PCYC's Shiller P/E is ranked higher than
93% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PCYC: 636.51 )
PCYC' s 10-Year Shiller P/E Range
Min: 504.62   Max: 7580.5
Current: 636.51

504.62
7580.5
Current Ratio 5.98
PCYC's Current Ratio is ranked higher than
78% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. PCYC: 5.98 )
PCYC' s 10-Year Current Ratio Range
Min: 0.14   Max: 49.32
Current: 5.98

0.14
49.32
Quick Ratio 5.69
PCYC's Quick Ratio is ranked higher than
78% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. PCYC: 5.69 )
PCYC' s 10-Year Quick Ratio Range
Min: 0.14   Max: 49.32
Current: 5.69

0.14
49.32

Valuation & Return

vs
industry
vs
history
Price/Net Cash 17.90
PCYC's Price/Net Cash is ranked higher than
78% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 50.00 vs. PCYC: 17.90 )
PCYC' s 10-Year Price/Net Cash Range
Min: 0.46   Max: 1650
Current: 17.9

0.46
1650
Price/Net Current Asset Value 16.11
PCYC's Price/Net Current Asset Value is ranked higher than
77% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 29.38 vs. PCYC: 16.11 )
PCYC' s 10-Year Price/Net Current Asset Value Range
Min: 0.46   Max: 825
Current: 16.11

0.46
825
Price/Tangible Book 13.85
PCYC's Price/Tangible Book is ranked higher than
67% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9.38 vs. PCYC: 13.85 )
PCYC' s 10-Year Price/Tangible Book Range
Min: 0.44   Max: 28.59
Current: 13.85

0.44
28.59
Price/DCF (Projected) 9.85
PCYC's Price/DCF (Projected) is ranked higher than
92% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PCYC: 9.85 )
PCYC' s 10-Year Price/DCF (Projected) Range
Min: 7.41   Max: 50
Current: 9.85

7.41
50
Price/Median PS Value 0.33
PCYC's Price/Median PS Value is ranked higher than
97% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. PCYC: 0.33 )
PCYC' s 10-Year Price/Median PS Value Range
Min: 0.24   Max: 15.64
Current: 0.33

0.24
15.64
Price/Graham Number 8.36
PCYC's Price/Graham Number is ranked higher than
90% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PCYC: 8.36 )
PCYC' s 10-Year Price/Graham Number Range
Min: 3.73   Max: 20.08
Current: 8.36

3.73
20.08
Earnings Yield (Greenblatt) 1.30
PCYC's Earnings Yield (Greenblatt) is ranked higher than
88% of the 1218 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. PCYC: 1.30 )
PCYC' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 13078.4
Current: 1.3

0.2
13078.4

Business Description

Industry: Biotechnology » Biotechnology
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:PY2.Germany,
Pharmacyclics Inc was incorporated in Delaware in 1991 and commenced operations in 1992. It is a biopharmaceutical company designing, developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. On November 13, 2013, the U.S. Food and Drug Administration (FDA) approved IMBRUVICA (ibrutinib, PCI-32765) as a monotherapy for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy and concurrently on November 13, 2013, the Company commercially launched IMBRUVICATM in the United States. The Company's competitors include major pharmaceutical and biotechnology companies, clinical reference laboratories and government agencies, as well as academic research institutions that are pursuing research activities similar to the company. The Company has contracted with a third-party logistics company to warehouse IMBRUVICATM and distribute it to wholesalers, distributors, pharmacies, hospitals, and other drug suppliers that ultimately distribute IMBRUVICATM directly to patients. The FDA and applicable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacture and marketing of pharmaceutical products.
» More Articles for PCYC

Headlines

Articles On GuruFocus.com
Weekly Insider Sells Highlight: BX, PCYC, MAS, ITMN Mar 03 2014 
comment on PCYC Mar 06 2013 
Weekly CEO Buys Highlight: PCYC, HLX, FSC, CREG, BTX Jun 25 2011 
Pharmacyclics Inc. Reports Operating Results (10-Q) Feb 08 2011 
Pharmacyclics Inc. Reports Operating Results (10-Q) Nov 09 2010 
Weekly CEO Buys Highlight: Pharmacyclics Inc, Saul Centers Inc, Charming Shoppes Inc, ProLogis, Exce Jun 27 2010 
Pharmacyclics Inc. Reports Operating Results (10-Q) May 07 2010 
cooldecency99 note on PCYC May 01 2010 
cooldecency99 note on PCYC May 01 2010 
Pharmacyclics Inc. Reports Operating Results (10-Q) Nov 03 2009 

More From Other Websites
Pharmacyclics Named 2014 Outstanding Company by BayBio Dec 12 2014
Pharmacyclics Named 2014 Outstanding Company by BayBio Dec 12 2014
PHARMACYCLICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Dec 11 2014
Pharmacyclics Presents Imbruvica Data at the ASH Meeting Dec 09 2014
UPDATE - IMBRUVICA® (ibrutinib) in Combination with Rituximab Data Shows Positive Benefit-Risk... Dec 09 2014
Longer Follow-Up IMBRUVICA® (ibrutinib) Treatment Demonstrates Sustained Efficacy in Patients with... Dec 09 2014
IMBRUVICA® (ibrutinib) Data Demonstrates Safety and Durability of Response at Two-Year Follow-up in... Dec 09 2014
IMBRUVICA® (ibrutinib) in Combination with Rituximab Data Shows Positive Benefit-Risk Profile in... Dec 09 2014
IMBRUVICA® (ibrutinib) Data Demonstrates Safety and Durability of Response at Two-Year Follow-up in... Dec 08 2014
IMBRUVICA® (ibrutinib) Data Demonstrates Safety and Durability of Response at Two-Year Follow-up in... Dec 08 2014
IMBRUVICA® (ibrutinib) in Combination with Rituximab Data Shows Positive Benefit-Risk Profile in... Dec 08 2014
Longer Follow-Up IMBRUVICA® (ibrutinib) Treatment Demonstrates Sustained Efficacy in Patients with... Dec 08 2014
IMBRUVICA® (ibrutinib) in Combination with Rituximab Data Shows Positive Benefit-Risk Profile in... Dec 08 2014
Pharmacyclics (PCYC) Launches U.S.-Based CLL Registry Dec 08 2014
Data From Phase 2 Clinical Trial of TG-1101 (Ublituximab) and Ibrutinib Shows Compelling Clinical... Dec 08 2014
IMBRUVICA® (ibrutinib) Data Suggests Promise in Multiple Myeloma Dec 06 2014
IMBRUVICA® (ibrutinib) Data Suggests Promise in Multiple Myeloma Dec 06 2014
Pharmacyclics Announces Launch of informCLL™ Registry for Chronic Lymphocytic Leukemia (CLL)... Dec 05 2014
Pharmacyclics Announces Launch of informCLL™ Registry for Chronic Lymphocytic Leukemia (CLL)... Dec 05 2014
Biotech stocks to watch at ASH Dec 05 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK